New therapeutic options for respiratory tract infections.

PURPOSE OF REVIEW:
The progressive increase of respiratory tract infections caused by multidrug-resistant organisms (MDROs) has been associated with delays in the prescription of an adequate antibiotic treatment and increased mortality, Continue reading New therapeutic options for respiratory tract infections.

Why Antibiotic Resistance is a Major Problem That Needs to be Addressed NOW

Over time, bacteria become resistant to antibiotics because the strains evolve very quickly, leaving people who suffer from infections with fewer treatment options. For people who have CF and are constantly dealing with bacterial Continue reading Why Antibiotic Resistance is a Major Problem That Needs to be Addressed NOW

Apta Biosciences Awarded H2020 EU Grant to Incorporate Seligo Technology into Next Generation Antibiotics and Infectious Disease Therapeutics

Apta Biosciences Ltd, is pleased to announce that it has been awarded an H2020 grant from the European Union in collaboration with the Austrian Institute of Technology (Vienna, Austria), Imperial College (London, UK), Aarhus University Continue reading Apta Biosciences Awarded H2020 EU Grant to Incorporate Seligo Technology into Next Generation Antibiotics and Infectious Disease Therapeutics

Antibiotic Resistance in Cystic Fibrosis Patients Explored Using Whole Genome Sequencing

In a recent study entitled “Comparative genomics of non-pseudomonal bacterial species colonising paediatric cystic fibrosis patients,” researchers performed a whole-genome profiling of bacterial strains, that are not Pseudomonas Continue reading Antibiotic Resistance in Cystic Fibrosis Patients Explored Using Whole Genome Sequencing

Arno Therapeutics’ AR-13 Shows Promise as Potential New Cystic Fibrosis Therapeutic Option for Serious Bacterial Infections

http://cysticfibrosisnewstoday.com/2015/09/25/arno-therapeutics-ar-13-shows-promise-potential-new-cystic-fibrosis-therapeutic-option-serious-bacterial-infections/

First published by Cystic Fibrosis News Today
By Charles Moore

Flemington, New Jersey based clinical stage biopharmaceutical company Arno Therapeutics, Inc. has announced data from a preclinical study demonstrating that its drug candidate AR-13, an analogue of Arno’s AR-12 infectious disease Continue reading Arno Therapeutics’ AR-13 Shows Promise as Potential New Cystic Fibrosis Therapeutic Option for Serious Bacterial Infections